FLT3 and acute myeloid leukemia: Alkynyl nicotinamide compounds HSN608 and HSN748 are more effective than FDA-approved FLT3 inhibitors against FLT3ITD in relapsed/refractory acute myeloid leukemia models bearing combination mutations.